Curapath is pleased to acknowledge the significant progress achieved by Macro Biologics, Inc., whose IND application for Amicidin‑α Surgical Gel has been accepted by the FDA, enabling the initiatio...
Polymeric excipients are key to advanced drug‑delivery systems, as their structure and impurity profile directly affect safety, stability, and in vivo performance. With rising regulatory expectation...
Curapath has partnered with Nacalai Tesque to expand access to its portfolio of next-generation polymers and PEG-free shielding lipids for advanced drug delivery applications in Japan.
Polymers are emerging as powerful alternatives to viral vectors for DNA delivery, enabling safer and more flexible approaches for DNA vaccines and in vivo CAR-T therapies.